Germany Exhibition Health (000813): Signing The Letter Of Intent Of Investment, The Company'S Chief Controller.

000813.SZ announces that in September 24, 2019, the company ("party a") signed the letter of intent to invest with Dai Yanzhen, the largest shareholder of Beijing Changjiang medical science and technology limited liability company ("Yangtze River pulse company") and its major shareholder, "the second party", in Beijing, and Dai Yanzhen and Beijing Changjiang medical science and Technology Co., Ltd.

Party A intends to establish cooperative relationship with Party B and the target company. The parties agree that the way to cooperate for the purpose of cooperation includes, but is not limited to, Party A's acquisition of the company's equity interests, or the increase in capital to the target company, so as to achieve the purpose of holding, and any other possible cooperation methods agreed by all parties.

The target company is a pioneer in the field of modern disinfection technology in China, serving as a professional service provider for professional disinfection in the fields of medical disinfection, public health and food hygiene. As of July 31, 2019, the total assets of the target company were 273 million yuan, net assets of 198 million yuan, and asset liability ratio of 27.47%.

The Yangtze River pulse company has been focusing on modern disinfection technology for more than 20 years, and has made comprehensive innovations in various fields of modern disinfection. It is the first innovative enterprise of disinfection technology in China. Its "Jian Zhi Su" disinfectant products have become the leading products in the industry, and are widely used in public health, health care, food and beverage drinking water industry, social service industry, military, railway, civil aviation, schools and other industries, families, travel and other civilian markets.

In the long run, the Yangtze River pulse company is expected to develop into the head enterprise of the industry. This investment will help the company expand its product pipeline, open up new profit growth points, enhance the company's overall competitiveness and profitability, and speed up the company's development speed.